Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: A new therapeutic strategy

Clinical Cancer Research

Volumn 2, Issue 12, 1996, Pages 1915-1920

  Grant, Steven ^a   Jarvis, W David ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN 1; CYTARABINE; MELPHALAN; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; SAFINGOL; STAUROSPORINE; VINCRISTINE;

APOPTOSIS; CANCER CHEMOTHERAPY; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CYTARABINE; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; LACTONES; MACROLIDES; NEOPLASMS; PROTEIN KINASE C; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 0030471559     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Salles, G , Shipp, M. A., and Coiffier, B. Chemotherapy of non-Hodgkin's aggressive lymphomas. Semin. Hematol., 31: 46-69, 1994.
2. Mastrianni, D. M., Tung, N. M , and Tenen, D. G. Acute myelogenous leukemia: current treatment and future directions Am. J. Med., 92: 286-295, 1992.
3. Klimo, P., and Connors, J. M. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J. Clin. Oncol., 3: 1174-1182, 1985.
4. Mackintosh, J., Coates, A., Swanson, C., Raghavan, D., and Tattersall, M. H. N. Chemotherapy of advanced colorectal cancer: a randomized trial of sequential methotrexate and fluorouracil. Am. J. Clin. Oncol., 10: 210-219, 1987.
5. Erlichman, C., Fine, S., Wong, A., and Elhakim, T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colon carcinoma. J. Clin. Oncol., 6: 469-476, 1988.
6. Fram, R., Major, P , Egan, E., Beardsley, P., Rosenthal, D., and Kufe, D. A Phase I-II study of combination therapy with thymidine and cytosine arabinoside. Cancer Chemother. Pharmacol., 11. 43-47, 1983.
7. Schwartzman, R. A., and Cidlowski, J. A. Apoptosis: the biochemistry and molecular biology of programmed cell death. Endocr. Rev., 14: 133-151, 1993.
8. Wyllie, A. H., Kerr, J. F. R., and Currie, A. R. Cell death: the significance of apoptosis. Int. Rev. Cytol., 68: 251-306, 1980.
9. Kerr, J. F. R., Winterford, C. M., and Harmon, B. V. Apoptosis: its significance in cancer and cancer therapy. Cancer (Phila.), 73: 2013-2016, 1994.
10. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science (Washington DC), 267: 1456-1462, 1995.
11. Searle, J., Kerr, J. F. R., and Bishop, C. J. Necrosis and apoptosis: distinct modes of cell death with fundamentally different significance. Pathol. Annu., 17: 229-259, 1982.
12. Duke, R. C., Chevernak, R., and Cohen, J. J. Endogenous endonuclease-induced DNA fragmentation: an early event in cell-mediated cytolysis. Proc. Natl. Acad. Sci. USA, 80: 6361-6365, 1983
13. Bicknell, G. R., Snowden, R. T., and Cohen, G. M. Formation of high molecular mass DNA fragments is a marker of apoptosis in the human leukemic cell line U937. J. Cell Sci., 107: 8 2483-2489, 1994.
14. Oppenheim, R. W. Naturally occurring cell death during neural development. Trends Neurosci., 8: 487-493, 1985.
15. Compton, M. M., and Cidlowski, J. A. Thymocyte apoptosis. A model of programmed cell death. Trends Endocrinol. Metab., 3: 17-23, 1992.
16. Wyllie A. H. Glucocorticoid-induced apoptosis is associated with endonuclease activation. Nature (Lond.), 284: 555-556, 1980.
17. Kaufmann, S. Induction of endonucleolytic DNA cleavage in human acute myeloid leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res., 48: 5870-5878, 1989.
18. Yang, S., Wang, C., Minden, M. D., and McCulloch, E. A. Fluorescence labeling of nicks in DNA from leukemic blast cells as a measure of damage following cytosine arabinoside: application to the study of drug sensitivity. Leukemia (Baltimore), 8: 2052-2059, 1994.
19. Ham, J., Babij, C., Whitfield, J., Pfarr, M., Lallemand, D., Yaniv, M., and Rubin, L. L. A c-jun dominant negative mutant protein protects sympathetic neurons against programmed cell death. Neuron, 14: 927-939, 1995.
20. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74: 957-967, 1993.
21. Miyashita, T., and Reed, J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in human leukemia cell line. Blood, 81: 151-157, 1993.
22. McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K. M., Green, D. R., and Cotter, T. G. BCR-ABL maintains resistance of chronic myeloid leukemia cells to apoptotic cell death. Blood, 83: 1179-1187, 1994.
23. Stabel, S., and Parker, P. J. Protein kinase C. Pharmacol. Ther., 51: 71-95, 1991.
24. Nishizuka, Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature, (Lond.), 308: 693-698, 1984.
25. Lotem, J., Cragoe, E. J., and Sachs, L. Rescue from programmed cell death in leukemia and normal cells. Blood, 78: 953-960, 1991.
26. Bertrand, R., Solary, E., O'Connor, P., Kohn, K. W., and Pommier, Y. Induction of a common pathway of apoptosis by staurosporine. Exp. Cell Res , 211: 314-321, 1994.
27. Jarvis, W. D., Turner, A. J., Povirk, L. F., Traylor, R. S., and Grant, S. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemic cells by pharmacological inhibitors of protein kinase C. Cancer Res , 54: 1707-1714, 1994.
28. Gorczyca, W , Gong, J., Ardelt, F., Traganos, R., and Darzynckiewicz, Z. The cell cycle-related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res., 53: 3186-3192, 1993.
29. Solary, E., Bertrand, R., Kohn, K. W., and Pommier, Y. Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase inhibitors. Blood. 81: 1353-1368, 1993.
30. Carroll, M. P., and May, W. S. Protein kinase C-mediated serine phosphorylation directly activates Raf-1 in murine hematopoietic cells. J. Biol. Chem., 269: 1249-1256, 1994.
31. + antiporter in suppression of apoptosis by granulocyte macrophage colony stimulating-factor and interleukin-3. J. Biol. Chem., 267: 9980-9987, 1992.
32. Eastman, A. Deoxyribonuclease II in apoptosis and the significance of intracellular acidification. Cell Death Differentiation, 1: 7-9, 1994.
33. Haldar, S., Jena, N., and Croce, C. M. Inactivation of Bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA, 92: 4352-4356, 1995.
34. Haldar, S , Chintapalli, J., and Croce, C. M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res., 56: 1253-1255, 1996.
35. Blagosklonny, M. V., Schulte, T., Nguyen, P., Trepel, J., and Neckers, L. M. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res., 56: 1851-1854, 1996.
36. May, W. S., Tyler, G., Ito, T., Armstrong, D. K., Qatsha, K. A., and Davidson, N. E. Interleukin-3 and bryostatin 1 mediate hyperphosphorylation of BCL2α in association with suppression of apoptosis. J. Biol. Chem., 269: 26865-26870, 1994.
37. cdc2 activation required for apoptosis. Science (Washington DC), 263: 1143-1145, 1994
38. Wang, Q., Worland, P. J., Clark, J. L., Carlson, B A , and Sauseville, E. A. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth & Differ., 6: 927-936, 1995.
39. Jarvis, D. W., Kolesnick, R. W., Fornari, F. A., Traylor, R. S., Gewirtz, D. A., and Grant, S. Activation of the sphingomyelinase pathway initiates apoptosis in a variety of mammalian cell lines. Proc. Natl. Acad. Sci. USA, 91: 73-77, 1994.
40. Obeid, L. M., Linardic, C. M., Karolak, L. A., and Hannun, Y. A. Programmed cell death induced by ceramide. Science (Washington DC), 259: 1769-1771, 1994.
41. Jarvis, W. D., Grant, S., and Kolesnick, R. N. Induction of cell death by ceramide. Clin. Cancer Res., 2: 1-6, 1996.
42. Verheij, M., Bose, R., Lin, X. H., Yao, B., Jarvis, W. D., Grant, S., Birrer, M. J., Szabo, E., Zon, L. I., Kyriakis, J. M., Haimovitz-Friedman, A., Fuks, Z , and Kolesnick, R. N. Environmental stresses signal apoptosis through a ceramide-initiated SAPK/JNK-mediated cascade. Nature (Lond), 380: 75-79, 1996.
43. Bose, R., Verheij, M., Haimovitz-Friedman, A., Scotto, K., Fuks, Z., and Kolesnick, R. Ceramide synthesis mediates daunorubicin-induced apoptosis: a new mechanism for generating cell death signals. Cell, 82: 405-414, 1995.
44. Strum, J. C., Small, G. W., Pauig, S. B., and Daniel, L. W. 1-β-D-arabinofuranosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells. J. Biol. Chem., 269: 15493-15497, 1994.
45. Jarvis, W. D., Fornari, F. A., Browning, J. L., Gewirtz, D. A., Kolesnick, R N., and Grant, S Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells. J. Biol. Chem., 269: 31685-31692, 1994.
46. Jarvis, W. D., Fornari, F., Traylor, R. S., Martin, H. A., Kramer, L. B., Erukulla, R. K., Bittman, R., and Grant, S. Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells. J. Biol. Chem., 271: 8275-8284, 1996.
47. Chmura, S. J., Nodzenski, E., Weichselbaum, R. R., and Quintans, J. Protein kinase C inhibition induces apoptosis and ceramide production through activation of a neutral sphingomyelinase. Cancer Res., 56: 2711-2714, 1996.
48. Martin, S. J., Takayama, S., McGahon, A. J., Miyashita, T., Corbeil, J., Kolesnick, R. N., Reed, J. C., and Green, D. R. Inhibition of ceramide-induced apoptosis by Bcl-2. Cell Death Differ., 2: 243-252, 1995.
49. Gunji, H., Kharbanda, S., and Kufe, D. Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells 1-β-D-arabinofuranosylcytosine. Cancer Res., 51: 741-743, 1991.
50. Kucera, G. L., and Capizzi, R. L. 1-β-D-arabinofuranosylcytosine-diphosphate is formed by the reversal of cholinephosphotransferase and not via cytidylyltransferase. Cancer Res., 52: 3886-3891, 1992.
51. Kharbanda, S., Datta, R., and Kufe, D. W. Regulation of c-jun gene expression in HL-60 leukemia cells by 1-β-D-arabinofuranosylcytosine. Potential involvement of a protein kinase C mechanism. Biochemistry, 30: 7947-7952, 1991.
52. Saleem, A., Datta, R., Yuan, Z-M., Kharbanda, S., and Kufe, D. Involvement of stress-activated protein kinase in the cellular response to 1-β-D-arabinofuranosylcytosine and other DNA-damaging agents. Cell Growth & Differ., 6: 1651-1658, 1995.
53. Emoto, Y., Kisaki, H., Manome, Y., Kharbanda, S., and Kufe, D. Activation of protein kinase Cγ in human myeloid leukemia cells treated with 1-β-D-arabinofuranosylcytosine. Blood, 87: 1990-1996, 1996.
54. Colatta, F., Polentarutti, M., Sironi, M., and Mantovani, A. Expression and involvement of c-fos and c-jun proto-oncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. J. Biol. Chem., 267: 18278-18283, 1992.
55. Bullock, G., Ray, S., Reed, J., Miyashita, T , Ibrado, A. M., Huang, Y., and Bhalla, K. Evidence against a direct role for the induction of c-jun expression in the mediation of drug-induced apoptosis in human acute leukemia cells. Clin. Cancer Res., 1: 559-564, 1995.
56. Grant, S., Turner, A., Bartimole, T. M., Nelms, P., Joe, V. C., and Jarvis, W. D. Modulation of 1-β-D-arabinofuranosylcytosine-induced apoptosis in human promyelocytic leukemia cells by staurosporine and other inhibitors of protein kinase C. Oncol. Res., 6: 87-99, 1994.
57. Freemerman, A. J., Turner, A. J., Birrer, M. J., Szabo, E., Valerie, K., and Grant, S. Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacologic inhibitors of protein kinase C. Mol. Pharmacol., 49: 788-795, 1996.
58. Hennings, H., Blumberg, P., Pettit, G., Herald, C., Shores, R., and Yuspa, S. Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis (Lond.), 8: 1343-1346, 1987.
59. Steube, K. G., and Drexler, H. G. Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C-activating agent bryostatin 1. Leuk. & Lymphoma, 9: 141-148, 1993.
60. Kraft, A. S., Smith, J. B., and Berkow, R. L. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc. Natl. Acad. Sci. USA, 83: 1334-1338, 1986.
61. u-protein kinase C to the nucleus of human promyelocytic leukemia (HL-60) cells J. Biol. Chem., 266: 28-33, 1991.
62. Jones, R., Sharkis, S., Miller, C., Rowinsky, E., Burke, P., and May, W. S. Bryostatin 1, a unique biological response modifier: antileukemic activity in vitro. Blood, 75: 1319-1323, 1990.
63. Hornung, R. L., Pearson, J. W., Beckwith, M., and Longo, D. L. Preclinical evaluation of bryostatin 1 as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res., 52: 101-107, 1992.
64. Prendiville, J., Crowther, D., Thatcher, N., Woll, P. J., Fox, B. W., McGown, A., Stern, P., McDermott, R., Potter, M., and Pettit, G. R. A Phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br. J. Cancer, 68: 418-424, 1993.
65. Grant, S., Jarvis, W. D., Swerdlow, P., Turner, A., Traylor, R., Wallace, H., Lin, P-S., Pettit, G. R., and Gewirtz, D. A. Potentiation of the activity of 1-β-D-arabinofuranosylcytosine by the macrocyclic lactone PKC activator bryostatin 1 is associated with enhanced fragmentation of mature DNA. Cancer Res., 52: 6270-6278, 1992.
66. Kishimoto, A., Kajikawa, N., Shiota, M., and Nishizuka, Y. Proteolytic activation of calcium-activated, phospholipid-dependent protein kinase by calcium-dependent neutral protease. I. Biol. Chem., 258: 1156-1164, 1983.
67. Isakov, N., Galron, D., Mustelin, T., Pettit, G. R., and Altman, A. Inhibition of phorbol ester-induced T-cell proliferation by bryostatin 1 is associated with rapid degradation of protein kinase C. J. Immunol., 150: 1195-1204, 1993.
68. Jarvis, W. D., Gewirtz, D. A., Povirk, L., Turner, A , Traylor, R., Pettit, G. R., and Grant, S. Effect of bryostatin 1 and other activators of protein kinase C on 1-β-D-arabinofuranosylcytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem. Pharmacol., 47: 839-852, 1994.
69. Ahmad, S., and Glazer, R. I. Expression of the antisense cDNA for protein kinase Cα attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol. Pharmacol., 43: 858-862, 1993.
70. Fine, R. L., Patel, J., and Chabner, B. A. Phorbol esters induce multidrug resistance in human breast cancer cells. Proc. Natl. Acad. Sci. USA, 85: 582-586, 1988.
71. Miyamoto, K., Inoko, K., Wakusawa, S., Kajita, S., Hasegawa, T., Takagi, K., and Koyama, M. Inhibition of multidrug resistance by a new staurosporine derivative, NA-382, in vitro and in vivo. Cancer Res., 53: 1555-1559, 1993.
72. Laredo, J., Huynh, A., Muller, C., Jaffrezou, J-P., Bailly, J-D., Cassar, G., Laurent, G., and Demur, C. Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells. Blood, 84: 229-237, 1994.
73. Basu, A., and Lazo, J S. Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1. Cancer Res., 52: 3119-3124, 1992.
74. Mohammad, R. M., Al-Katib, A., Pettit, G. R., and Sensenbrenner, L. L. Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res., 54: 165-168, 1994.
75. Schwartz, G. K., Haimovitz-Friedman, A., Dhupar, S. K., Ehleiter, D., Maslak, P., Lai, L., Loganzo, F., and Kelsen, D. P. Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells. J. Natl. Cancer Inst., 87: 1394-1399, 1995.
76. Markovits, J., Larsen, A. K., Segal-Bendirdjian, E., Fosse, P., Saucier, J. M., Gazit, A., Levitzki, A., Umezawa, K., and Jacquemin-Sablon, A. Inhibition of DNA topoisomerases I and II and induction of apoptosis by erbstatin and tyrphostin derivatives. Biochem. Pharmacol., 48: 549-560, 1994.
77. Teofili, L., Pierelli, L., Iovino, M. S., Leone, G., Scambia, G., De Vincenzo, R., Benedetti, P. P., Menichella, G., Macri, E., Piantelli, M., Ranelletti, F. O., and Larocca, L. M. The combination of quercetin and cytosine arabio noside synergistically inhibits leukemic cell growth. Leuk. Res., 16: 497-505, 1992.
78. Ponnathpur, V., Ibrado, A. M., Reed, J. C., Ray, S., Huang, Y., Self, S., Bullock, G., Nawabi, A., and Bhalla, K. Effects of modulators of protein kinases on Taxol-induced apoptosis of human leukemia cells possessing disparate levels of p26BCL-2 protein. Clin. Cancer Res., 1: 1399-1406, 1995.
79. neu expressing non-small cell lung cancer cells. Cancer Res , 56: 1068-1074, 1996.